Gastrointestinal Diseases, Healthy
Conditions
Keywords
Prebiotics
Brief summary
Human Milk Oligosaccharides (HMOs) are the third most abundant class of nutrients in human milk. Studies investigating the effects of dietary HMOs in infants have shown various health and developmental benefits such as the development of the early gut microbiome (by favouring colonisation of beneficial Bifidobacterium, Lactobacillus, and Bacteroides), the development of the immune system, general infant growth, protection against infectious diseases and allergies, and stimulation of cognitive development. Only a limited number of studies have been conducted in adults, showing intake of HMOs stimulates the growth of gut Bifidobacterium in healthy adults.
Detailed description
The current study aims to investigate the effects of a 4-week intervention with two HMOs on gut microbiome composition, immune function and gastrointestinal symptoms in healthy adults with mild to moderate gastrointestinal complaints. The study will be conducted as a partially decentralized, double-blind, randomized, placebo-controlled, parallel group design.
Interventions
DIETARY_SUPPLEMENTPlacebo
Consume placebo (Maltodextrin) once daily before going to bed for 28 days
DIETARY_SUPPLEMENTHMO 1
Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
DIETARY_SUPPLEMENTHMO 2
Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
Sponsors
Kyowa Hakko Bio Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 40 and ≤ 55 years * Male/female * Total score of \>2 on the Gastrointestinal Symptom Rating Scale (GSRS) * Body Mass Index 18-30 kg/m2 * Stable body weight (± 5%) for at least 6 months * Stable lifestyle and dietary habits within the 4 weeks prior and during study period * Owns device (computer, smartphone, tablet) with access to the internet * Adequate fluency in the English language to understand the inform consent process, study instructions and study assessments * Sufficient vision and hearing to complete study procedures * Willing and able to participate, follow the study procedures and to give written informed consent
Exclusion criteria
* History (\< 6 months prior to the study) or presence of severe gastrointestinal, metabolic, immunological, psychiatric disorder, or major surgery * Current or past (\< 4 weeks) use of prescription, over-the-counter, or traditional medication, or dietary supplements with a relevant impact on GI system or on visceral motility * Having received antibiotic treatment \< 4 weeks prior to study * Alcohol intake \>1 units/day * Currently pregnant or pregnancy in past 6 months * Use of pro/prebiotics \< 4 weeks prior to study start * Fully vegetarian/vegan diet \< 4 weeks prior to study start * High habitual vegetable and fruit intake (\> 2 servings of fruits and \>2 servings of vegetables per day) \< 4 weeks prior to study start * Lactose intolerance * Maltodextrin allergy * Members of the research team or their immediate family members. Immediate family member is defined as spouse, parent, child, or sibling, whether biological or legally adopted
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative abundance of Bifidobacterium in the gut | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Relative abundance of other bacterial taxa in the gut | 4 weeks |
| Gut microbiome functional potential (functional metagenomics analyses) | 4 weeks |
| Stool Human Milk Oligossacharides level | 4 weeks |
| Concentration of immune parameters panel in blood (OLINK Target 96 Inflammation panel) | 4 weeks |
Other
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal Symptoms Questionnaire | 4 weeks | — |
| Depression Anxiety Stress Scale (DASS)-21 items | 4 weeks | — |
| Digestion-associated Quality of Life Questionnaire (DQLQ) | 4 weeks | — |
| Bristol stool chart | 4 weeks | Stool consistency ranging from Type 1 to Type 7 |
| Clinical chemistry and haematology analyses for safety analysis | 4 weeks | — |
Countries
Singapore
Outcome results
None listed